About Zacharon Pharmaceuticals
Zacharon Pharmaceuticals is a company based in San Diego (United States) founded in 2004 was acquired by BioMarin Pharmaceutical in January 2013.. Zacharon Pharmaceuticals has raised $4.05 million across 11 funding rounds from investors including BioMarin Pharmaceutical, NIH and HHS. Zacharon Pharmaceuticals offers products and services including Glycan-Targeted Drugs, Drug Development Platform, and Sensi-Pro Assay. Zacharon Pharmaceuticals operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Zacharon Pharmaceuticals, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$4.05 M (USD)
in 11 rounds
-
Latest Funding Round
$33 K (USD), Series A
Mar 30, 2012
-
Investors
BioMarin Pharmaceutical
& 3 more
-
Employee Count
Employee Count
-
Acquired by
BioMarin Pharmaceutical
(Jan 07, 2013)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Zacharon Pharmaceuticals
Zacharon Pharmaceuticals offers a comprehensive portfolio of products and services, including Glycan-Targeted Drugs, Drug Development Platform, and Sensi-Pro Assay. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Small molecule drugs for treating lysosomal storage diseases and cancer.
Platform for discovering glycan-targeted treatments via screening.
Assay for detecting lysosomal storage diseases through partnerships.
Funding Insights of Zacharon Pharmaceuticals
Zacharon Pharmaceuticals has successfully raised a total of $4.05M across 11 strategic funding rounds. The most recent funding activity was a Series A round of $33 thousand completed in March 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 11
- Last Round Series A — $33,000
-
First Round
First Round
(11 Sep 2008)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2012 | Amount | Series A - Zacharon Pharmaceuticals | Valuation |
investors |
|
| Mar, 2012 | Amount | Grant - Zacharon Pharmaceuticals | Valuation |
investors |
|
| May, 2011 | Amount | Grant - Zacharon Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Zacharon Pharmaceuticals
Zacharon Pharmaceuticals has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include BioMarin Pharmaceutical, NIH and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Drug discovery services are provided to the biopharma sector.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Zacharon Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Zacharon Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Zacharon Pharmaceuticals Comparisons
Competitors of Zacharon Pharmaceuticals
Zacharon Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Zacharon Pharmaceuticals
When was Zacharon Pharmaceuticals founded?
Zacharon Pharmaceuticals was founded in 2004 and raised its 1st funding round 4 years after it was founded.
Where is Zacharon Pharmaceuticals located?
Zacharon Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Zacharon Pharmaceuticals?
Robin M Jackman is the current CEO of Zacharon Pharmaceuticals.
Is Zacharon Pharmaceuticals a funded company?
Zacharon Pharmaceuticals is a funded company, having raised a total of $4.05M across 11 funding rounds to date. The company's 1st funding round was a Grant of $2M, raised on Sep 11, 2008.
What does Zacharon Pharmaceuticals do?
Zacharon Pharmaceuticals was founded in 2004 in San Diego, United States, within the biotechnology sector. Small molecule therapeutics were developed to target glycan biosynthesis, supported by a platform integrating cell-based screening and glycan structural analysis for drug discovery. Programs addressed heparan sulfate inhibitors for mucopolysaccharidosis III and ganglioside inhibitors for Tay-Sachs and Sandhoff diseases. Acquisition by BioMarin occurred in January 2013 for 10 million.
Who are the top competitors of Zacharon Pharmaceuticals?
Zacharon Pharmaceuticals's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Zacharon Pharmaceuticals offer?
Zacharon Pharmaceuticals offers Glycan-Targeted Drugs, Drug Development Platform, and Sensi-Pro Assay.
Who are Zacharon Pharmaceuticals's investors?
Zacharon Pharmaceuticals has 4 investors. Key investors include BioMarin Pharmaceutical, NIH, HHS, and Avalon Bio Ventures.